Novocure limitedNVCR.US Overview
NVCR Overall Performance
NVCR AI Analysis & Strategy
Browsing restrictions can be lifted for a fee.
NVCR Key Information
NVCR Financial Forecast
Browsing restrictions can be lifted for a fee.
| Quarterly | EPS Forecast | QoQ | Max | Min |
|---|---|---|---|---|
| 2025Q1 | ||||
| 2025Q2 | ||||
| 2025Q3 | ||||
| 2025Q4 | ||||
| 2026Q1 |
NVCR Earnings Table
Unit : USD
| QTR | Non-GAAP EPS | EPS YoY | EPS Surprise % | Sales | Sales YoY | Sales Surprise % | NPM |
|---|---|---|---|---|---|---|---|
| Current | |||||||
| 2024Q4 | |||||||
| 2024Q3 | |||||||
| 2024Q2 | |||||||
| 2024Q1 |
NVCR Profile
NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Europe, the Middle East, Africa, Japan, and Greater China. Its TTFields devices include Optune for the treatment of glioblastoma; and Optune Lua for the treatment of malignant pleural mesothelioma. The company also has ongoing or completed clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. NovoCure Limited was incorporated in 2000 and is headquartered in Saint Helier, Jersey.
Price of NVCR
NVCR FAQ
When is NVCR's latest earnings report released?
The most recent financial report for Novocure limited (NVCR) covers the period of 2025Q3 and was published on 2025/09/30. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating NVCR's short-term business performance and financial health. For the latest updates on NVCR's earnings releases, visit this page regularly.
What is the operating profit of NVCR?
According to the latest financial report, Novocure limited (NVCR) reported an Operating Profit of -36.02M with an Operating Margin of -21.54% this period, representing a decline of 12.24% compared to the same period last year. Operating Profit reflects the company's core business efficiency and cost control, making it a key indicator for evaluating operational strength and profitability.
How is NVCR's revenue growth?
In the latest financial report, Novocure limited (NVCR) announced revenue of 167.2M, with a Year-Over-Year growth rate of 7.81%. Revenue growth can be driven by product mix changes, market share expansion, price adjustments, or international market penetration. Investors should also monitor gross margin and regional revenue distribution for a comprehensive view of growth quality and sustainability.
How much debt does NVCR have?
As of the end of the reporting period, Novocure limited (NVCR) had total debt of 797.94M, with a debt ratio of 0.59. Short-term debt comprises a higher/lower proportion. The level of financial leverage directly impacts the company's capital structure and interest coverage. If debt is high, pay attention to interest expenses and refinancing risks. Conversely, a low-leverage structure indicates greater risk tolerance but potentially less growth flexibility.
How much cash does NVCR have?
At the end of the period, Novocure limited (NVCR) held Total Cash and Cash Equivalents of 344.64M, accounting for 0.25 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.
Does NVCR go with three margins increasing?
In the latest report, Novocure limited (NVCR) did not achieve the “three margins increasing” benchmark, with a gross margin of 73.2%%, operating margin of -21.54%%, and net margin of -22.3%%. This demonstrates limited improvement in profitability, which is a key signal for fundamental analysis. Investors should consider margin trends alongside other financial indicators to assess NVCR's profit trajectory and future growth potential.
Is NVCR's EPS continuing to grow?
According to the past four quarterly reports, Novocure limited (NVCR)'s earnings per share (EPS) shows a declining trend, with the latest EPS at -0.33. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.
What is the FCF of NVCR?
Novocure limited (NVCR)'s Free Cash Flow (FCF) for the period is 14.92M, calculated as Operating Cash Flow minus Capital Expenditures, representing a rise of 4,959.61% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.
What are the PEG ratio and PE ratio of NVCR?
The latest valuation data shows Novocure limited (NVCR) has a Price-To-Earnings (PE) ratio of -8.08 and a Price/Earnings-To-Growth (PEG) ratio of 1.16. A PEG below 1 usually suggests the market is underestimating growth potential, while a PEG above 1 indicates high growth expectations are already priced in. Investors should conduct a comprehensive valuation by considering historical growth, market forecasts, and industry cycles.